Skip to main content
SpringerLink
Log in
Book cover

Renal Cell Carcinoma

Translational Biology, Personalized Medicine, and Novel Therapeutic Targets

  • Book
  • © 2012

Overview

Editors:
  1. Robert A. Figlin

    1. David Geffen School of Medicine at UCLA, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. W. Kimryn Rathmell

    1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Brian I. Rini

    1. Taussig Cancer Institute, Department of Solid Tumor Oncology, Cleveland Clinic, CLEVELAND, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Provides a comprehensive look at renal cell carcinoma

  • Explores renal cell carcinoma biology

  • Discusses future molecular targets for renal cancer carcinoma

  • Includes supplementary material: sn.pub/extras

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (15 chapters)

  1. Front Matter

    Pages i-xi
    Download chapter PDF

  2. Biology of Renal Cell Carcinoma

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies

      • Laura S. Schmidt, Ramaprasad Srinivasan, W. Marston Linehan
      Pages 3-25

    3. Molecular Biology of Clear Cell Renal Carcinoma

      • William G. Kaelin Jr.
      Pages 27-47

    4. HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment

      • W. Kimryn Rathmell
      Pages 49-68

    5. Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC

      • Brittany Bahamon, Sabina Signoretti
      Pages 69-89

    6. Molecular Characterization of Renal Cell Carcinoma

      • Bin Tean Teh, Leslie J. Farber, Kyle Furge
      Pages 91-111

  3. Current and Future Molecular Targets for RCC

    1. Front Matter

      Pages 113-113
      Download chapter PDF

    2. Targeting the VEGF Pathway in Renal Cell Carcinoma

      • Cristina Suarez, Brian I. Rini
      Pages 115-133

    3. Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma

      • C. Lance Cowey, Thomas E. Hutson
      Pages 135-160

    4. Research Translation and Personalized Medicine

      • James Brugarolas
      Pages 161-191

    5. Epigenetic Targeting and Histone Deacetylase Inhibition in RCC

      • Swathi Ramakrishnan, Roberto Pili
      Pages 193-211

    6. C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma

      • Hema Vankayala, Patricia LoRusso, Ulka Vaishampayan
      Pages 213-238

    7. Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies

      • Sumanta Kumar Pal, Karen Reckamp, Hua Yu, Robert A. Figlin, Robert A. Figlin, Robert A. Figlin
      Pages 239-252

    8. Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma

      • E. Oosterwijk, A. B. Stillebroer, P. F. A. Mulders
      Pages 253-270

    9. Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials

      • Hyung L. Kim, Edwin M. Posadas, Robert A. Figlin, Robert A. Figlin, Robert A. Figlin
      Pages 271-282

    10. Mechanisms of Resistance to VEGF-Directed Therapy and Implications for Future Trial Design

      • James W. Mier
      Pages 283-303

    11. Vaccine-Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma

      • Johannes Vieweg
      Pages 305-322

  4. Back Matter

    Pages 323-327
    Download chapter PDF
Back to top

Keywords

About this book

This book provides a comprehensive look at renal cell carcinoma, exploring its biology as well as current and future molecular targets for renal cancer carcinoma.

Reviews

From the reviews:

“The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. … certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC.” (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013)

“Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. … We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase.” (European Urology Today, June-July, 2012)

“This book by Figlin et al. is … timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. … We found it comprehensive, well written and well illustrated. … Overall, we found this to be an excellent book that we highly recommend. … It would be equally well placed on the shelf of physicians and researchers … and those with an interest in the field would do well to have read it.” (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)

Editors and Affiliations

  • David Geffen School of Medicine at UCLA, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA

    Robert A. Figlin

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA

    W. Kimryn Rathmell

  • Taussig Cancer Institute, Department of Solid Tumor Oncology, Cleveland Clinic, CLEVELAND, USA

    Brian I. Rini

Bibliographic Information

  • Book Title: Renal Cell Carcinoma

  • Book Subtitle: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets

  • Editors: Robert A. Figlin, W. Kimryn Rathmell, Brian I. Rini

  • DOI: https://doi.org/10.1007/978-1-4614-2400-0

  • Publisher: Springer New York, NY

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Science+Business Media, LLC 2012

  • Hardcover ISBN: 978-1-4614-2399-7Published: 01 March 2012

  • Softcover ISBN: 978-1-4899-9139-3Published: 13 April 2014

  • eBook ISBN: 978-1-4614-2400-0Published: 28 February 2012

  • Edition Number: 1

  • Number of Pages: XII, 328

  • Topics: Cancer Research, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation